The FDA has raised concerns about concentrated 7-OH products because of their opioid-like effects and potential for dependence. Published clinical reports have also documented withdrawal associated with their use.
Patients experiencing difficulty reducing or stopping these products should seek an individualized medical assessment. Research into treatment approaches remains limited.
Original sources
- FDA (July 29, 2025). FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers.
- Wightman and Hu. Journal of Addiction Medicine (2026). A Case of 7-Hydroxymitragynine Use Requiring Inpatient Medically Managed Withdrawal.
Explore treatment options
Learn about kratom and 7-OH treatment · See all research updates
Research summaries are provided for education and do not replace individualized medical advice.
Request an appointment